These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 1329975)

  • 1. Regulation of topoisomerase II by murine mastocytoma cells.
    Collett AG; Ralph RK
    Biochim Biophys Acta; 1992 Oct; 1132(3):259-64. PubMed ID: 1329975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence that a protein kinase enhances amsacrine mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei.
    Darkin-Rattray SJ; Ralph RK
    Biochim Biophys Acta; 1991 Feb; 1088(2):285-91. PubMed ID: 1848107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between sensitivity to 4'-(9-acridinylamino)methanesulfon-m-anisidide and DNA topoisomerase II in a cold-sensitive cell-cycle mutant of a murine mastocytoma cell line.
    Schneider E; Hutchins AM; Darkin SJ; Lawson PA; Ralph RK
    Biochim Biophys Acta; 1988 Nov; 951(1):85-97. PubMed ID: 2847799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A protein factor that enhances amsacrine-mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei.
    Darkin SJ; Ralph RK
    Biochim Biophys Acta; 1989 Apr; 1007(3):295-300. PubMed ID: 2539190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function.
    Per SR; Mattern MR; Mirabelli CK; Drake FH; Johnson RK; Crooke ST
    Mol Pharmacol; 1987 Jul; 32(1):17-25. PubMed ID: 3037302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutations at arg486 and glu571 in human topoisomerase IIalpha confer resistance to amsacrine: relevance for antitumor drug resistance in human cells.
    Patel S; Keller BA; Fisher LM
    Mol Pharmacol; 2000 Apr; 57(4):784-91. PubMed ID: 10727526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells.
    Ganapathi R; Zwelling L; Constantinou A; Ford J; Grabowski D
    Biochem Biophys Res Commun; 1993 May; 192(3):1274-80. PubMed ID: 8389546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
    DeVore RF; Corbett AH; Osheroff N
    Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein.
    Granzen B; Graves DE; Baguley BC; Danks MK; Beck WT
    Oncol Res; 1992; 4(11-12):489-96. PubMed ID: 1363724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
    Lanza A; Tornaletti S; Stefanini M; Evans HH; Ricanati M; Astaldi Ricotti GC; Pedrini AM
    Carcinogenesis; 1993 Sep; 14(9):1759-63. PubMed ID: 8403196
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative activity of structural analogues of amsacrine against human leukemia cell lines containing amsacrine-sensitive or -resistant forms of topoisomerase II: use of computer simulations in new drug development.
    Zwelling LA; Mitchell MJ; Satitpunwaycha P; Mayes J; Altschuler E; Hinds M; Baguley BC
    Cancer Res; 1992 Jan; 52(1):209-17. PubMed ID: 1309224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
    Lelièvre S; Benchokroun Y; Larsen AK
    Mol Pharmacol; 1995 May; 47(5):898-906. PubMed ID: 7746278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effects of genistein and amsacrine on leukemia cell proliferation.
    Finlay GJ; Holdaway KM; Baguley BC
    Oncol Res; 1994; 6(1):33-7. PubMed ID: 7919550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.
    Barret JM; Calsou P; Larsen AK; Salles B
    Mol Pharmacol; 1994 Sep; 46(3):431-6. PubMed ID: 7935322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced amsacrine-induced mutagenesis in plateau-phase Chinese hamster ovary cells, with targeting of +1 frameshifts to free 3' ends of topoisomerase II cleavable complexes.
    Patteson K; Wang P; Povirk LF
    Cancer Res; 1999 Aug; 59(15):3682-8. PubMed ID: 10446982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons.
    Smith PJ; Bell SM; Dee A; Sykes H
    Carcinogenesis; 1990 Apr; 11(4):659-65. PubMed ID: 2157558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of DNA intercalators to overcome topoisomerase II-mediated multidrug resistance.
    Baguley BC; Holdaway KM; Fray LM
    J Natl Cancer Inst; 1990 Mar; 82(5):398-402. PubMed ID: 2154584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of resistance of non-cycling mammalian cells to 4'-[9-acridinylamino]methanesulphon-m-anisidide: role of DNA topoisomerase II in log- and plateau-phase CHO cells.
    Schneider E; Darkin SJ; Robbie MA; Wilson WR; Ralph RK
    Biochim Biophys Acta; 1988 Mar; 949(3):264-72. PubMed ID: 2831986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.